Fredun Pharmaceuticals Limited, a prominent player in the pharmaceutical and healthcare industry, has recently been the subject of considerable attention due to its robust performance and strategic market positioning. As of September 17, 2026, the company’s close price stood at INR 1,305.85, reflecting a significant recovery from its 52-week low of INR 403.717 recorded on September 23, 2025. This resurgence underscores the company’s resilience and adaptability in a highly competitive market.
Headquartered in Mumbai, India, Fredun Pharmaceuticals Limited was established in 1987 and has since expanded its footprint across diverse regions, including India, Africa, Southeast Asia, the Commonwealth of Independent States, the MENA region, and Latin America. The company’s extensive product portfolio encompasses pharmaceutical formulations, dietary and herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, and mobility and rehabilitation products, among others.
A key aspect of Fredun Pharmaceuticals’ strategy is its comprehensive range of allopathic formulations. These include a wide array of therapeutic categories such as analgesics, NSAIDs, antacids, antiulcer, anthelmintic, antibacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressants, antifungal, antihistamines, antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators, anti-asthma drugs, calcium tablets, cardiovascular drugs, diuretics, impotence drugs, laxatives, and appetite stimulants with multivitamins. This diverse product range not only caters to a broad spectrum of healthcare needs but also positions the company as a versatile player in the pharmaceutical sector.
In addition to its pharmaceutical offerings, Fredun Pharmaceuticals provides a variety of surgical products, including IV fluids, cannulas, disposable syringes, infusion sets, surgical gloves, and cottons. The company also supplies active pharmaceutical ingredients (APIs), direct compressible granules, pellets, and animal healthcare products, further diversifying its market presence.
A notable innovation in Fredun Pharmaceuticals’ product lineup is its Hormone Range Products, a specialty therapeutics brand that focuses on longevity, hormone health, recovery science, and human performance solutions. This brand exemplifies the company’s commitment to advancing healthcare through cutting-edge research and development.
With a market capitalization of INR 21,950,384,128 and a price-to-earnings ratio of 66.0984, Fredun Pharmaceuticals demonstrates strong financial health and investor confidence. The company’s strategic initiatives and expansive product portfolio are likely to drive sustained growth and market leadership in the coming years.
As Fredun Pharmaceuticals continues to navigate the complexities of the global healthcare landscape, its emphasis on innovation, quality, and strategic expansion positions it well to capitalize on emerging opportunities and address the evolving needs of its diverse customer base.
